Dr. Dajun Yang, Ascentage Pharma CEO, joins 'Closing Bell Overtime' to talk today's IPO. Marilyn Manson won’t face sexual ...

Shares of liquefied natural gas exporter Venture Global debuted Friday below their initial public offering price of $25 per ...

Sionna Therapeutics aims to raise $100 million in an IPO for cystic fibrosis drugs, backed by venture capital, targeting a ...

In 2024, global and US markets saw a slight increase in IPOs. Syntax Data used its FIS classification system to analyze the ...

The year 2025 is expected to see a resurgence of IPOs due to policy changes, monetary easing, and a favorable business ...

The Trump administration has made very clear they support growing LNG exports,” Venture CEO Mike Sable told CNBC in an ...

The tepid reception to Venture Global's ambitious valuation target shows companies need to set realistic expectations when ...

Shares of Ascentage Pharma Group International rose as much as 4% in the Chinese biopharmaceutical company’s US trading debut ...

Venture Global Inc. shares are indicated to open as much as 6% above their IPO price, after the natural gas exporter raised ...

After what many considered a “slow” year for IPOs, January has ushered in a string of biotechs filing to go public. But 2024 ...

The U.S. IPO market is expected to see a blowout 2025, fueled by the return of business-friendly Donald Trump to the White ...